| Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. | |
| | |
MedLine Citation:
|
PMID: 21061834 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Angiotensin II regulates the production of adipokines. The objective was to study the effect of treatment with irbesartan versus olmesartan in obese hypertensive women. SUBJECTS: A sample of 34 obese hypertensive women was analyzed in a prospective way with a randomized trial. Patients were randomized to irbesartan (300 mg/day) or olmesartan (40 mg/day) for 3 months. Weight, body mass index, blood pressure, basal glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, HOMA and visfatin were determined at basal time and after 3 months of treatment. RESULTS: Thirty four patients gave informed consent and were enrolled in the study. A significative decrease in systolic and diastolic blood pressures was reached without changes in weight. Patients treated with olmesartan had a significative decrease of total cholesterol, LDL cholesterol, insulin, HOMA and visfatin levels. Decrease in total cholesterol and LDL cholesterol was similar with both angiotensin receptor blockers. Decrease in insulin (2.28 +/- 2.77 vs 0.66 +/- 4.4 mUI/L: p < 0.05), HOMA (0.69 +/- 1.1 vs 0.48 +/- 1.6 units: p < 0.05) and visfatin (5.16 +/- 13 vs 1.85 +/- 9.1 ng/ml: p < 0.05) levels was higher in olmesartan than irbesartan group. CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. |
| | |
Authors:
|
D A De Luis; R Conde; M Gonzalez Sagrado; R Aller; O Izaola; J L Perez Castrillon; E Romero; M J Castro |
Related Documents
:
|
6177964 - Open assessment of the effect of prazosin on plasma lipids. 19375714 - Sugar-sweetened beverages, serum uric acid, and blood pressure in adolescents. 8061854 - Effects of antihypertensive medication on hypertension in patients with sleep apnoea. 20538744 - Reductions in risk factors for secondary prevention of coronary heart disease by ethnic... 3396974 - Use of ferrokinetics in the follow-up of patients with polycythaemia vera. 8567384 - Evaluation of five common induction protocols by comparison of hemodynamic responses to... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: European review for medical and pharmacological sciences Volume: 14 ISSN: 1128-3602 ISO Abbreviation: Eur Rev Med Pharmacol Sci Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-11-10 Completed Date: 2010-12-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9717360 Medline TA: Eur Rev Med Pharmacol Sci Country: Italy |
Other Details:
|
Languages: eng Pagination: 759-63 Citation Subset: IM |
Affiliation:
|
Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega. RD-056/0013 RETICEF, University of Valladolid, Valladolid, Spain. dadluis@yahoo.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin II Type 1 Receptor Blockers / therapeutic use* Antihypertensive Agents / therapeutic use* Biological Markers / blood Biphenyl Compounds / therapeutic use* Blood Glucose / metabolism Blood Pressure / drug effects Body Mass Index Body Weight Cholesterol / blood Cytokines / blood* Female Humans Hypertension / blood, complications, drug therapy*, physiopathology Imidazoles / therapeutic use* Insulin / blood Middle Aged Nicotinamide Phosphoribosyltransferase / blood* Obesity / blood, complications*, physiopathology Prospective Studies Spain Tetrazoles / therapeutic use* Time Factors Treatment Outcome Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biological Markers; 0/Biphenyl Compounds; 0/Blood Glucose; 0/Cytokines; 0/Imidazoles; 0/Tetrazoles; 0/Triglycerides; 0/olmesartan; 11061-68-0/Insulin; 138402-11-6/irbesartan; 57-88-5/Cholesterol; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12/nicotinamide phosphoribosyltransferase, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-ma...
Next Document: Antiinflammatory and antioxidant activities of gum mastic.